Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.

Purpose: In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathoph...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nutrition Vol. 58; no. 4; pp. 1735 - 1746
Autores principales: Bomhof, Marc R., Parnell, Jill A., Ramay, Hena R., Crotty, Pam, Rioux, Kevin P., Probert, Chris S., Jayakumar, Saumya, Raman, Maitreyi, Reimer, Raylene A.
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Jun2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136938812&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 136938812
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14366207
        CR0
      jtl: European Journal of Nutrition
      issn: 14366207
      maglogo: N
    pubinfo:
      dt: Jun2019
      vid: 58
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        136938812
        136938812
        136938812
        10.1007/s00394-018-1721-2
        136938812
      ppf: 1735
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.
      aug:
        au:
          Bomhof, Marc R.
          Parnell, Jill A.
          Ramay, Hena R.
          Crotty, Pam
          Rioux, Kevin P.
          Probert, Chris S.
          Jayakumar, Saumya
          Raman, Maitreyi
          Reimer, Raylene A.
        affil: Department of Kinesiology and Physical Education, University of Lethbridge, 4401 University Drive, T1K 3M4, Lethbridge, AB, Canada
      sug:
        subj:
          Dietary Supplementation
          Prebiotics Therapeutic Use
          Nonalcoholic Fatty Liver Disease Diet Therapy
          Nonalcoholic Fatty Liver Disease Diagnosis
          Human
          Randomized Controlled Trials
          Pilot Studies
          Biopsy Methods
          Treatment Outcomes
          Body Weight Changes
          Body Composition
          Glucose Tolerance Test
          Inflammation
          Biological Markers
          Gut Microbiota
          Weight Loss
          Fructose
          Bifidobacterium
          Clostridium
          Life Style Changes
      ab: Purpose: In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH. Methods: In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota. Results: Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (P = 0.016). Bifidobacterium was enhanced by oligofructose, whereas bacteria within Clostridium cluster XI and I were reduced with oligofructose (P < 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease. Conclusions: Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted. Clinical Trial: This trial was registered at Clinicaltrials.com as NCT03184376.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N